FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:913-915 August 27, 2009 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Reichlin, T. Related Article by Keller, T. PubMed Citation

Despite the pervasive measurement of cardiac troponin for the diagnosis of myocardial infarction, the continued evolution of assays and guidelines for their application has created uncertainty among many practitioners regarding the use of cutoff values for clinical interpretation. As such, many clinicians may not welcome more sensitive assays for troponin. Nevertheless, professional societies have advocated for improved analytic performance of commercial assays, resulting in a current generation of widely used troponin assays that are more sensitive than their predecessors. In this issue of the Journal, important studies by Keller et al.¹ and Reichlin et al.² reveal the advantages and limitations . . . [Full Text of this Article]

Source Information

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston.

This article has been cited by other articles:

• (2009). Clinical Performance of Newer, More-Sensitive Troponin Assays. JWatch Emergency Med. 2009: 1-1 [Full Text]